GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (BSP:A1ZN34) » Definitions » Cyclically Adjusted Price-to-FCF

AstraZeneca (BSP:A1ZN34) Cyclically Adjusted Price-to-FCF : 67.55 (As of May. 23, 2024)


View and export this data going back to 2020. Start your Free Trial

What is AstraZeneca Cyclically Adjusted Price-to-FCF?

As of today (2024-05-23), AstraZeneca's current share price is R$67.55. AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was R$1.00. AstraZeneca's Cyclically Adjusted Price-to-FCF for today is 67.55.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BSP:A1ZN34' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 12.25   Med: 25.15   Max: 73.79
Current: 65.55

During the past years, AstraZeneca's highest Cyclically Adjusted Price-to-FCF was 73.79. The lowest was 12.25. And the median was 25.15.

BSP:A1ZN34's Cyclically Adjusted Price-to-FCF is ranked worse than
72.2% of 313 companies
in the Drug Manufacturers industry
Industry Median: 33.44 vs BSP:A1ZN34: 65.55

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AstraZeneca's adjusted free cash flow per share data for the three months ended in Mar. 2024 was R$0.469. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is R$1.00 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted Price-to-FCF Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.17 48.06 60.81 62.36 57.15

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.90 62.58 58.91 57.15 56.63

Competitive Comparison of AstraZeneca's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted Price-to-FCF falls into.



AstraZeneca Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AstraZeneca's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=67.55/1
=67.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.469/131.6000*131.6000
=0.469

Current CPI (Mar. 2024) = 131.6000.

AstraZeneca Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.277 99.800 0.365
201409 0.473 100.000 0.622
201412 0.478 99.900 0.630
201503 -0.475 99.600 -0.628
201506 0.179 100.100 0.235
201509 0.623 100.200 0.818
201512 0.018 100.400 0.024
201603 0.432 100.400 0.566
201606 -0.370 101.000 -0.482
201609 0.191 101.500 0.248
201612 0.582 102.200 0.749
201703 -0.122 102.700 -0.156
201706 -0.035 103.500 -0.045
201709 0.779 104.300 0.983
201712 0.193 105.000 0.242
201803 -0.204 105.100 -0.255
201806 -0.146 105.900 -0.181
201809 0.108 106.600 0.133
201812 0.927 107.100 1.139
201903 -0.579 107.000 -0.712
201906 -0.047 107.900 -0.057
201909 0.399 108.400 0.484
201912 0.516 108.500 0.626
202003 -0.147 108.600 -0.178
202006 0.041 108.800 0.050
202009 0.766 109.200 0.923
202012 0.816 109.400 0.982
202103 1.043 109.700 1.251
202106 0.343 111.400 0.405
202109 0.623 112.400 0.729
202112 0.422 114.700 0.484
202203 1.524 116.500 1.722
202206 0.380 120.500 0.415
202209 1.020 122.300 1.098
202212 1.033 125.300 1.085
202303 0.925 126.800 0.960
202306 0.640 129.400 0.651
202309 1.179 130.100 1.193
202312 0.747 130.500 0.753
202403 0.469 131.600 0.469

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (BSP:A1ZN34) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AstraZeneca Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (BSP:A1ZN34) Business Description

Industry
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (BSP:A1ZN34) Headlines

No Headlines